Streetbeat News

Products Services

TTOO

T2 Biosystems, Inc. (NASDAQ:TTOO) shares rose after announcing FDA 510(k) clearance for the expanded T2Bacteria Panel, which now includes detection of Acinetobacter baumannii. This addition enhances the panel's coverage to approximately 75% of sepsis-causing pathogens. The company is set to report Q4 financial results soon. The stock's movement is also discussed in the context of technical analysis, with its 200-day moving average noted.

Portfolio Pulse from Erica Kollmann

February 12, 2024 | 4:52 pm

TTOO

T2 Biosystems' stock is trading higher following the announcement that the FDA has granted 510(k) clearance for the expanded T2Bacteria panel, indicating regulatory approval for an enhanced version of their diagnostic tool.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 4:38 pm

AAPL

GOOG

IWM

NVDA

SPY

The article discusses the potential of small caps, represented by the iShares Russell 2000 ETF (IWM), highlighting their performance relative to the S&P 500 and factors that could influence their future performance. It also covers early trade money flows for several major companies and ETFs, including positive flows for NVIDIA (NVDA), neutral for Apple (AAPL), Amazon (AMZN), Meta Platforms (META), and Microsoft (MSFT), negative for Alphabet (GOOG) and Tesla (TSLA), and mixed for SPDR S&P 500 ETF Trust (SPY) and Invesco QQQ Trust (QQQ). Additionally, it mentions the performance of Bitcoin, gold, and oil, with specific ETFs for gold (GLD) and oil (USO) mentioned.

Portfolio Pulse from The Arora Report

February 12, 2024 | 4:37 pm

NNOX

Nano-X Imaging's shares are experiencing an uptick following the FDA 510(k) approval received by its subsidiary, Nano-X AI, for the HealthFLD system, designed to detect early signs of fatty liver disease.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 4:32 pm

MELI

Investors have shown a bearish stance on MercadoLibre (NASDAQ:MELI) through unusual options trading activity, with a sentiment split of 26% bullish and 73% bearish. The trading targets a price range of $1240.0 to $2000.0 for MELI over the next three months. The company, which operates Latin America's largest e-commerce marketplace, has seen its stock price slightly increase by 0.04%, with an upcoming earnings announcement in 14 days.

Portfolio Pulse from Benzinga Insights

February 12, 2024 | 4:31 pm

BTCUSD

Grayscale Investments reports the upcoming Bitcoin halving event is distinct due to recent regulatory approvals of spot Bitcoin ETFs, leading to mainstream adoption and potentially reducing selling pressure. The report highlights increased onchain activity and anticipates continued growth driven by developer interest and innovations on the Bitcoin blockchain. Miners have prepared by raising funds and selling reserves. Historical macro-economic events have previously driven investors towards Bitcoin. Analysts note a struggle for Bitcoin to surpass the $48,000 mark, with varying opinions on future price movements.

Portfolio Pulse from Khyathi Dalal

February 12, 2024 | 4:23 pm

APD

Air Products (APD) has signed a 10-year Power Purchase Agreement (PPA) with Eneco for solar electricity in The Netherlands, marking a significant step towards sustainability. This agreement will see APD sourcing the majority of its energy needs for liquid nitrogen and oxygen production from the Vlagtwedde Solar PV farm, reducing emissions equivalent to the carbon footprint of about 45,000 households. This move aligns with APD's long-term vision for decarbonizing the industrial gases sector and its previous commitments to sustainability in Europe.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 4:03 pm

AMGN

Financial analysis reveals a bearish trend in Amgen's (NASDAQ:AMGN) options trading, with 53% of traders showing bearish tendencies. Significant trades indicate a targeted price range of $290.0 to $305.0. Amgen, a biotech leader, has a diverse portfolio including drugs for cancer, inflammatory diseases, and rare diseases. The stock is currently down -0.38% at $290.01, with analysts giving mixed ratings but an average target price of $338.6. Options trading suggests cautious investor sentiment despite Amgen's strong market standing and analyst support.

Portfolio Pulse from Benzinga Insights

February 12, 2024 | 4:00 pm

ABT

EW

FDA advisors will discuss Abbott Laboratories' TriClip G4 System for severe tricuspid regurgitation (TR) on February 13, 2024. Despite the TRILUMINATE trial meeting its primary endpoint, FDA reviewers raised concerns about the trial's unblinded design and the potential placebo effect on patient-reported outcomes. Earlier, Edwards Lifesciences received FDA approval for its Evoque tricuspid valve replacement system without an advisory committee, based on positive TRISCEND II study results. ABT shares fell 0.38% to $111.38.

Portfolio Pulse from Vandana Singh

February 12, 2024 | 4:00 pm

ASML

INTC

SSNLF

TSM

ASML Holding NV showcased its advanced €350 million chipmaking machine, ordered by Intel Corp for its Oregon factory, aiming for production by late 2025. This machine, critical for AI advancements, etches semiconductor lines as thin as 8 nanometers. ASML's technology has seen record orders, including from Samsung Electronics and Taiwan Semiconductor Manufacturing Co, reflecting strong industry optimism. ASML reported a 12.5% year-on-year increase in Q4 2023 net sales, with China being its largest market.

Portfolio Pulse from Anusuya Lahiri

February 12, 2024 | 3:58 pm